Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 2

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 2
---
 corporation and a wholly owned subsidiary of Parent (the “Merger”). The Merger Agreement contemplates that the Merger will be effected pursuant to Section 251(h) of the DGCL, which permits completion of the Merger without a stockholder vote promptly following consummation of the Offer. At the effective time of the Merger (the “Effective Time”), each Target Share (other than (i) Target Shares owned by the Target (or held in the treasury of the Target), Parent, Merger Sub or any of their respective subsidiaries or (ii) Target Shares that are held by stockholders who are entitled to, and properly demand, appraisal for such Target Shares in accordance with Section 262 of the DGCL) will be cancelled and converted into the right to receive the Offer Price from Merger Sub (the “Merger Consideration”) without interest, subject to any applicable withholding tax. The
closing of the Merger is expected to occur by the end of January 2026, subject to the satisfaction of customary closing conditions.

The obligations of Parent and Merger Sub to consummate the Offer is
subject to the satisfaction or waiver of a number of conditions set forth in the Merger Agreement, including that there have been validly
tendered and not validly withdrawn prior to the expiration of the Offer a number of Target Shares that, considered together with the number
of Target Shares, if any, then owned beneficially by Parent and its subsidiaries, would represent one more Target Share than 50% of the
total number of Target Shares outstanding at the time of expiration of the Offer (the “Minimum Condition”). The Minimum Condition
may not be waived by Parent and Merger Sub without the prior written consent of the Target. In addition, the obligation of Merger Sub
to consummate the Offer is conditioned upon, among other things, the accuracy of the representations and warranties of the Target contained
in the Merger Agreement (subject to certain materiality exceptions), material compliance by the Target with its covenants under the Merger
Agreement and the expiration or termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended (the “HSR Act”) and the receipt of all approvals and clearances required thereunder and other customary closing
conditions. Consummation of the Offer is not subject to a financing condition.

Each party to the Merger Agreement has agreed to make an appropriate
filing of a Notification and Report Form pursuant